Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evo

TAVI benefits were attenuated and mortality trended higher in PARTNER 3 at 5 years. For Evolut, TAVI maintained an edge.

Related Keywords

Boston , Massachusetts , United States , New York , Houston , Texas , Gilbert Tang , Pinak Shah , David Cohen , Michael Reardon , Edwards Lifesciences , Kendra Grubb , Bernard Prendergast , Drug Administration , Md Emory University , Presbyterian Columbia University Irving Medical Center , Md Cardiovascular Research Foundation St , Md Methodist Debakey Heart Vascular Center , Journal Of The American College Cardiology , Mount Sinai Health System , Columbia University Irving Medical Center , New England Journal , Emory University , Evolut Low Risk , Methodist Debakey Heart , Vascular Center , Sapien Ultra , Cleveland Clinic London , Cardiovascular Research , Francis Hospital , American College , Evolut Low Risk Trial ,